In a phase II clincal trial of treating metastatic melanoma with modified HLA-A2*0201 bound gp100:209–217(210 M) peptide vaccine in combination with cytokine interlekin-2 (IL-2), the glycoprotein carrier can be replaced with our SOMV platform to introduce bacterial immunotherapy as a combination treatment of melanoma [29]. The gene discussed is PMEL; the disease is metastatic melanoma.